Gilead Sciences | GILD - Ebitda

Stock Price
129.58
Daily Change
-2.48 -1.88%
Monthly
-6.47%
Yearly
26.42%
Q2 Forecast
126.98

Gilead Sciences reported $3.02B in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
AbbVie USD 5.37B 1.85B Dec/2025
Agios Pharmaceuticals USD -120.31M 4.82M Dec/2025
ALKERMES USD 80.26M 20.05M Mar/2026
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amgen USD 5.14B 775M Dec/2025
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Gilead Sciences USD 3.02B 1.01B Dec/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
Incyte USD 367.97M 46.53M Mar/2026
J&J USD 7.19B 2.32B Dec/2025
Merck USD 6.3B 2.09B Dec/2025
Moderna USD -790M 582M Dec/2025
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Novartis USD 5.3B 530M Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
PTC Therapeutics USD -70.99M 91.62M Dec/2025
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Sanofi EUR 3.31B 3.65B Mar/2026
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
United Therapeutics USD 379.5M 83.4M Dec/2025
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026